Lv1
50 积分 2026-05-21 加入
AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial
7小时前
待确认
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
15天前
已完结
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
28天前
已完结
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)
1个月前
已完结
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
IL-33 enhances responsiveness and mast cell mediator release in isolated human small airways
2个月前
已完结
Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications
2个月前
已完结
T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma
2个月前
已完结
A rational approach to compare and select biologic therapeutics in asthma
2个月前
已完结
Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation
2个月前
已完结
皖公网安备34019202002308
